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Objective: To systematically review and quantify the effectiveness of interventions in reducing caries development during 
orthodontic treatment and evaluate the quality of evidence for the development of clinical guidelines.  
Materials and methods: A comprehensive literature search of the Cochrane, EMBASE and MEDLINE databases was conducted 
to identify eligible randomised controlled trials (RCTs). The risk of bias was assessed using the Cochrane risk of bias (RoB 2) 
tool. In order to facilitate the development of clinical guidelines, the quality of the evidence was assessed using Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE).  
Results: A total of 18 RCTs were included in the qualitative synthesis, of which 10 had a high risk of bias, and eight had minor 
concerns. Three RCTs that investigated the efficacy of fluoride interventions during fixed orthodontic treatment were included in 
the quantitative synthesis. The pooled effect size resulted in a risk reduction of 0.23 (95% CI: -0.35, -0.11, p < 0.001) in the 
intervention group compared to controls. The GRADE evaluation identified the evidence as moderate due to the limited number of 
RCTs and moderate heterogeneity (I-squared statistic of 49.3%).  
Conclusions: Although fluoride is the most effective evidence-based preventive intervention during orthodontic treatment, large 
RCTs are required to provide high quality evidence. Further studies are needed to evaluate the caries preventive effects of oral 
hygiene programs, chlorhexidine, CPP-ACP and other interventions.  
(Aust Orthod J 2021; 37: 14 - 30. DOI: 10.21307/aoj-2021-002)
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Introduction
An increased risk of dental caries is a recognised 
adverse effect of orthodontic treatment. A recent study 
identified the incidence of white spot lesion (WSL) 
development during removable aligner treatment as 
1.2%, and 26% with fixed appliances.1 The presence 
of orthodontic appliances creates niches for biofilms 
to develop and persist. In the presence of a cariogenic 
diet, undisturbed biofilms lead to an ecological shift 
and the creation of an acidic environment resulting 
in demineralisation and the development of carious 
lesions.2 Incipient carious lesions present clinically 
as opaque WSLs. Untreated WSLs may progress to 
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irreversible tooth destruction, which necessitates 
restorative management with on-going maintenance, 
significant costs and future disease burdens.3 
Three meta-analyses (MA) and seven systematic 
reviews (SR) have been conducted to investigate 
the preventive effects of various interventions.4-13 
The reports investigated fluoride (F), chlorhexidine 
(CHX), and casein phosphopeptide amorphous 
calcium phosphate (CPP-ACP). However, split 
mouth studies contributed to 50% of the quantitative 
analysis presented in one MA.11 These studies 
were significantly confounded due to carry-across 
effects, which produced bias in treatment efficacy 
estimates.14,15 Additionally, there were no statistical 
tests to detect the carry-across effect.15 Two SRs 
investigated post-orthodontic WSL inhibition, rather 
than prevention, which is the focus of the present 
SR.10,13 Two SRs included non-randomised controlled 
trials (RCTs), and one did not conduct a risk of bias 
assessment, which significantly affected their internal 
validity.6,7,12 A Cochrane review identified the need for 
measuring treatment effect over the entire duration of 
orthodontic treatment, to prevent an overestimation 
of efficacy.5 However, this review investigated the 
effects of F alone, and could not perform meta-
analyses. Additional analyses comparing short- and 
long-term effects were lacking in another SR.9 
Moreover, recent preventive interventions such as self-
assembling peptides (SAPs) have not been investigated 
within SRs. SAPs putatively show promising 
remineralisation effects by providing a template for 
mineral precipitation, but evidence is limited.16-18
Therefore, the present systematic review aimed to 
assess and compare the preventive effects of various 
emerging and conventional interventions aimed to 




The review protocol was devised a priori and registered 
in the International Prospective Register of Systematic 
Reviews (PROSPERO; CRD42019137627).
Eligibility criteria
The PICO framework was:
Participants: Orthodontic patients undergoing fixed 
or removable orthodontic treatment, without age or 
gender restrictions. 
Interventions:
• Topical F: toothpaste/ dentifrice, mouth rinse, 
gel, and varnish. The following formulations 
were included: sodium fluoride (NaF), sodium 
monofluorophosphate (SMFP), stannous fluoride 
(SnF
2
), acidulated phosphate fluoride (APF) and 
amine fluoride (AmF).
• F releasing adhesives and elastomeric ligatures.
• Products containing CHX, CPP-ACP and CPP-
ACPF.
• Other calcium products: tricalcium phosphate 
(TCP) and nano-hydroxyapatite.
• Resin modified glass ionomer cement (RMGIC) 
coating.
• SAP.
• Oral hygiene and dietary modifications.
Comparison: Either placebo or another treatment. 
Outcomes: The primary outcomes were incidence of 
WSLs and their inhibition (arrest and/or reversal), as 
measured using either ICDAS or DMFT. The total 
number of carious lesions at the end compared to the 
start of the study was utilised to obtain a risk ratio.
The secondary outcomes included differences in 
lesion size between control and intervention groups. 
This was measured at the end of the study, using 
quantitative light induced fluorescence (QLF). Self-
reports of adverse events, side-effects and tolerability 
were also recorded. 
For binary outcomes (absence or presence of WSLs), 
the relative risk (RR) was computed at 95% confidence 
intervals (CI). For continuous data (change in mean 
scores of WSLs from start to end of the study), the 
mean difference was calculated at 95% CI. 
Study design
English language RCTs in humans from 1970 to June 
2019, with a duration of at least six months, were 
included. Exclusion criteria were non-randomised 
designs, laboratory-based (in vitro, in vivo and ex 
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vivo), retrospective, split mouth studies and trials that 
did not record WSLs at the onset and at the end of 
treatment. Post-orthodontic WSL inhibition studies 
were also excluded.
Information sources and literature search
A systematic search of Embase, MEDLINE and 
Cochrane Central Register of Controlled Trials 
(CENTRAL) was performed. The search strategy 
is provided in Supplementary Table I. Unpublished 
studies were sought by searching ClinicalTrials.gov. 
The reference lists of included papers were hand 
searched to screen for relevant studies. 
Study selection
Following the removal of duplicates, the titles and 
abstracts were screened for inclusion. Relevant articles 
had their full texts assessed to determine suitability for 
inclusion or exclusion. The study selection was done 
independently by two authors (JM and MS) (Figure 
1). A third author (DM) was contacted to confirm the 


















selection of the 
reported result
Overall bias
Ogaard et al. (1997) High Low Low Some 
concerns
Low High





Jenatschke et al. (2001) Some concerns Low Low Some 
concerns
Some concerns Some concerns
Weiss et al. (2005) Some concerns Some 
concerns
Low High Some concerns High
Ogaard et al. (2006) Some concerns Low Low Low Low Some concerns
Steckson-Blicks et al. 
(2007)
Some concerns Low Low Low Some concerns Some concerns
Al Mulla et al. (2010) Some concerns Low Low High Some concerns High
Jiang et al. (2013) Low Low Low Low Some concerns Some concerns
Fretty (2014) Low Low Low High Some concerns High
Sonesson et al. (2014) Low Some 
concerns
Low Low Some concerns Some concerns
Hoffman et al. (2015) Some concerns Low High High Some concerns High
Suetenkov et al. (2015) Some concerns Some 
concerns
Low High Some concerns High
van der Kaaij et al. 
(2015)
Low Low Low Low Some concerns Some concerns
Esenlik et al. (2016) High Some 
concerns
High High Some concerns High
Zotti et al. (2016) Low Low Low Low Some concerns Some concerns
Alavi et al. (2018) Some concerns Some 
concerns
High High Some concerns High
Gómez et al. (2018) High Low Some 
concerns
Low Some concerns High
Rechmann et al. (2018) Low Some 
concerns
Low Low Low Some concerns
Table I.  Risk of bias assessment of RCTs included in the qualitative analysis.
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Data collection and data items
Data extraction was performed by the first author 
(JM) using Excel (Microsoft, 2019, Chicago), and 
audited by MS. Disagreements were resolved by 
discussion with DM. Data items included sample 
size, age of participants, intervention, comparison, 
frequency of intervention, follow-up period, outcome 
measure, baseline and outcome data. When required, 
authors were contacted via email correspondence for 
clarification of missing data. 
Risk of bias in individual trials
The Cochrane RoB 2 tool was used to evaluate bias 
in the included RCTs.19 This tool evaluates bias across 
five domains: the randomisation process, deviations 
from intended interventions, missing outcome data, 
measurement of the outcome, and selection of the 
reported result. 
Summary measures and approach to data 
synthesis
Statistical heterogeneity was assessed by the I2 statistic, 
with significance set at p < 0.05. These statistical 
analyses and meta-analysis were performed using 
Jamovi (an open statistical software) with a random-
effects model, due to expected heterogeneity.20
Additional analyses
Following NHMRC recommendations, GRADE was 
used to determine the quality of evidence, to facilitate 
the development of a clinical guideline for the 
prevention of WSLs during orthodontic treatment.21 
Publication bias was planned for assessment using 
funnel plots, if more than 10 studies were included in 
the quantitative analysis. Subgroup analyses for age, 
gender, preventive measure, outcome measure and 
type of appliance were planned.
Search key words
1 Prevent*
2 Fluoride* or toothpaste* or tooth paste or mouthrinse* or mouth rinse* or mouth wash* or gel or varnish or NaF or SMFP 
or SnF or APF or amine F or f releas* or dentrific*
3 tooth brushing or dental devices, home care/
4 Exp cariostatic agents/ or cariostatic
5 Chlorhexidine or chlor hexidine
6 CPP ACP or casein phosphopeptide amorphous calcium phosphate
7 RMGI or resin modified glass ionomer*
8 SAP or self assembling peptide*
9 Oral hygiene or OHI
10 Or/1-9
11 caries or incipient lesion* or WSL or cavity or cavities or white spot
12 demineralization or demineralisation
13 or/11-12
14 fixed or orthodont* or brace* or edgewise or begg
15 removable or removed or appliance*
16 exp orthodontics/
17 or/ 14 -16
18 10 AND 13 AND 17
19 randomized controlled trial.pt
20 controlled clinical trial.pt
21 random* or blind*
22 trial or trials
23 or/19 - 22
24 18 AND 23
25 limit 24 to English language
Supplementary Table I.  MEDLINE OVID search strategy.
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Results
Study selection 
A total of 2494 citations were identified through the 
searches. Following duplicate removal, 1430 articles 
were available for title and abstract screening. This 
led to the exclusion of 1368 studies. Subsequently, 
62 articles had their full texts read. Based on the pre-
determined inclusion/exclusion criteria, 44 articles 
were excluded (Supplementary Table II), and 18 RCTs 
were included in the qualitative analysis. Following 
the risk of bias assessment, three RCTs were pooled 
for quantitative synthesis. The study selection process 
is illustrated in Figure 1. 
Study characteristics
The characteristics of the 18 RCTs included in the 
qualitative analysis are summarised in Supplementary 
Table III. Ten trials investigated F, three assessed 
CHX, two CPP-ACP, two oral hygiene, and one 
assessed laser intervention.22-39 
Following the RoB assessment, three RCTs were 
included in the quantitative analysis, since the rest 
were heterogeneous and at high RoB.25,27,31 Included 
studies had a total of 433 patients (10–20 years of 
age), of which 216 participants were allocated to the 
intervention group. 
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             









        
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
For more informa+on, visit www.prisma-statement.org. 































Records excluded by title and 
abstract 
(n=1368) 




Reviews and meta-analysis (n=105) 
In-vivo (n=92) 
Effect on bond strength only (n=50) 
Split-mouth design (n=47) 
Effect on pathogens only (n=30) 
Post-orthodontic (n=27) 
Effect on plaque only (n=23) 
Ex-vivo* (n=19) 
Non-human (n=19) 





Articles excluded after full text 
assessed 
(n = 44) 
Non-RCT (n=12) 
Baseline data unavailable (n=9) 
Follow up < 6 months (n=8) 
Split-mouth design (n=7) 
Ex-vivo* (n=3) 
Different topic (n=2) 
In-vitro (n=2) 
Outcome data unavailable (n=1) 
Studies included in 
qualitative synthesis 
(n=18)




Figure 1. PRISMA flowchart presenting the study selection and identification process. 
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Study Reason for exclusion
Dimitriadis AG, Sassouni V, and Draus FJ (1974). Non randomised
Boyd RL (1992). Non randomised
Boyd RL (1993). Non randomised
Turner PJ (1993). Non randomised
Banks PA and Richmond S (1994). Split mouth
Boyd RL and Rose CM (1994). Non randomised
Silverman E,  Cohen M, Demke RS, and Silverman M (1995). Non randomised
Trimpeneers LM and Dermaut LR (1996). Non randomised
Marini I, Pellicioni GA, Vecchiet F, Bonetti GA, Checchi L. (1999). Baseline data not available
Wenderoth CJ,  Weinstein M, and Borislow AJ (1999). Split mouth
Banks PA, Chadwick SM, Asher-McDade C, Wright JL (2000). Baseline data not available
Hsu CYS, Jordan TH, Dederich DN, and Wefel JS (2000). Non randomised
Harazaki M, Hayakawa K, Fukui T, Isshiki Y, and Powell LG (2001). Non randomised
Ogaard B, Larsson E, Henriksson T, Birkhed D, and Bishara SE (2001). Baseline data not available
Donly KJ (2003). Ex-vivo
Zimmer BW and Rottwinkel Y (2004). Non randomised
Abdullah AZ, Stafford SM, Brookes SJ, and Duggal MS (2006). In-vitro
Miura KK, Ito IY, Enoki C, Elias AM, and Matsumoto MAN (2007). < 6 months
Shafi I (2008). Non- randomised
Dong YN, Chen M, and Ren XM (2009). Split mouth
Tenuta LMA, Zamataro CB, Del Bel Cury AA, Tabchoury CPM, and Cury JA (2009). Split mouth
Akkurt MD, Amasyali M,  Ozcan S, Yagci A, Basak F, and Sagdic D (2011). < 6 months
Buck T, Pellegrini P, Sauerwein R, Leo MC, Covell Jr DA, Maier T, and Machida CA (2011). Split mouth
Demito CF, Rodrigues GV, Ramos AL, and Bowman SJ (2011). Split mouth
Najibfard K, Chedjieu I, Ramalingam K, and Amaechi BT (2011). < 6 months
Stafford GL (2011). Non- randomised
Sollenius O, Karlsson L, Petersson LG, and Twetman S (2013). < 6 months
Atwa ALDA,. AbuShahba RY, Mostafa M, and Hashem MI (2014). < 6 months
Melo MA, Morais WA, Passos VF, Lima JP, and Rodrigues LK (2014). In-vitro
Ghajari MF, Eslamian L, Rad AN, and Morovati SP (2015). Baseline data not available
Masoud MI, Allarakia R, Alamoudi NM, Nalliah R, and Allareddy V (2015). Outcome data not available
Paschoal MA, Moura CMZ, Jeremias F, Souza JF, Bagnato VS, Giusti JSM, and Santos-Pinto L (2015). < 6 months
Restrepo M, Bussaneli DG, Jeremias F, Cordeiro RCL, Magalhaes AC, Palomari Spolidorio DM, and 
Santos-Pinto L (2015). Ex-vivo
Zhang N, Chen C, Weir MD, Bai Y, and Xu HH (2015). Ex-vivo
Bussaneli DG, Jeremias F, Cordeiro RC, Raveli DB, Magalhaes AC, Candolo C, and Santos-Pinto L 
(2016). < 6 months
Gizani S, Petsi G, Twetman S, Caroni C, Makou M, Papagianoulis L (2016). Baseline data not available
Hammad  S and Abdellatif A (2016). Baseline data not available
Miller CC, Burnside G, Higham SM, Flannigan NL (2016). Baseline data not available
Oosterkamp BCM, Wafae A, Schols JGJH, van der Sanden WJM, and Wensing M (2016). Different topic
Korkmaz YN and Yagci A (2018). < 6 months
Liptak L, Szabo K, Nagy G, Marton S, and Madlena M (2018). Split mouth
Benson PE, Alexander-Abt J, Cotter S, Dyer F, Fenesha F, Patel A, Campbell C, Crowley N & Millett D 
(2019). Baseline data not available
Enerback H, Moller M, Nylen C, Odman Bresin C, Ostman Ros I, and Westerlund A (2019). Different topic
Sonesson M, Brechter A, Abdulraheem S, Lindman R, Twetman S (2019). Baseline data not available
Supplementary Table II.  Reasons for exclusion following full-text assessment.
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Risk of bias within studies
The eighteen RCTs were assessed for RoB 
(Table I). Ten studies were determined to 
have a high RoB and were excluded from the 
quantitative synthesis.22,23,26,28,30,33,34,35,38,39 This led 
to the consideration of eight RCTs for meta- 
analysis.24,25,27,29,31,32,36,37
Results of individual studies and data 
synthesis
Of the eight trials considered for quantitative synthesis, 
five evaluated the same intervention – topical F 
application.24,25,27,29,31 The five RCTs identified a 
reduction in WSL development. The other trials 
investigated chlorhexidine, oral hygiene, and CPP-
ACP.32,36,37 A slight reduction in WSL incidence was 
obtained by these interventions, which was reported 
as non-significant. The studies could not be pooled 
for meta-analysis, since they were heterogeneous 
interventions. 
Of the five F intervention RCTs, three used placebo 
controls.25,27,31  The other two RCTs used F in their 
intervention and comparison arms.24,29 One RCT 
compared a toothpaste combining SnF
2 
and AmF to 
a NaF toothpaste with the same F concentration.24 
While another compared two toothpastes of different 
F concentration.29 Since these studies prevented the 
estimation of effect size, it was decided to synthesise 
data from the three trials that compared the effects of 
F to a placebo.25,27,31 
Two studies compared the effect of professionally 
applied F.25,27 They investigated the effects of a six-
weekly application of 0.9% difluorsilane (1000 ppm 
F) in a polyurethane varnish base and a two-monthly 
application of 12,300 ppm APF foam.25,27 Conversely, 
the effect of daily at-home use of a 250 ppm NaF 
rinse was investigated using quantitative light induced 
fluorescence (QLF) by another trial.31 Compliance 
with the use of a mouthrinse was not recorded. The 
F interventions were supplementary to standard 
oral hygiene practice of twice daily brushing with a 
fluoridated toothpaste.
In the three RCTs, a clinical assessment was performed 
under artificial white lighting following plaque 
removal.25,27,31 Patients with developmental defects of 
enamel (DDE) such as hypoplasia and fluorosis were 
excluded in one study.27 The other two RCTs did not 
consider DDE.25,31 The diagnosis and assessment of 
WSLs differed between the studies. The teeth were 
dried with sterile gauze prior to clinical examination 
in one RCT.27 Clinical photographs were taken after 
drying the teeth in two RCTs.25,31 The bonding 
materials used to attach appliances varied between the 
RCTs.  One study did not provide this information.31 
Resin composite was used in one trial, while the other 
study used a resin applied as a pre-coated bracket 
(Victory Twin APC II bracket, 3M Unitek, CA, 
USA).25,27  All three RCTs had some concerns related 
to RoB (Figure 2). 
The pooled effect size from the random-effects model 
showed a risk difference of -0.23 (95% CI: -0.35, 
-0.11, p < 0.001; Figure 3). A 23% reduction in WSL 
incidence was obtained with F interventions. Similar 
results were obtained using a fixed-effects model 
(Supplementary Figure 1). Statistical heterogeneity 
was moderate at 49.3% (Figure 4). Only one study 
investigated the effect of F on lesion size.31 Since 
there were no WSLs at the start of the study for these 
participants, the effect on lesion inhibition could not 
be ascertained. 
Additional analyses
The publication and reporting biases were not analysed 
since fewer than ten studies were included in the 
meta-analysis. Subgroup analyses were not conducted 
due to insufficient data. A pooled adverse effect profile 
for F could not be constructed, since only one study 
reported adverse events, of which there were none.27 
Clinical guideline
Quality of evidence (GRADE)
The findings from the quantitative analysis of 
the three included RCTs were used for grading F 
interventions.25,27,31 The quality of evidence for 
CHX, CPP-ACP, oral hygiene program and laser 
interventions were graded from the initial full-texts 
analysed. This included the RCTs and observational 
studies. 
According to the GRADE evaluation, a moderate 
quality of evidence for the use of F during orthodontic 
care was obtained (Figure 5). Quality was downgraded 
to moderate due to statistical heterogeneity and a 
small number of RCTs. Very low-quality evidence was 
obtained for CHX, CPP-ACP, oral hygiene program 
and laser therapy, due to non-randomised studies 
that were sponsor funded and measured surrogate 
outcomes (Figure 5).
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Figure 2. Risk of bias summary of studies included in the meta-analysis.
Figure 3. Meta-analysis of WSL risk reduction with fluoride interventions, using a random-effects model. The forest plot shows the pooled effect of fluoride 
on WSL incidence. 
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Resource use and economic evaluation 
(GRADE)
The primary resource to evaluate is the intervention, 
both in-chair and at-home. The cost of F interventions 
may vary within and across countries, and could be 
shared by governments, private insurers and patients. 
A cost-benefit analysis regarding F for caries prevention 
has not been conducted previously. Therefore, an 
economic evaluation could not be performed in the 
present review. Since these caries preventive resources 
are not labour intensive, a resource use evaluation 
may not be important in developing clinical 
recommendations.
Clinical recommendations (GRADE)
For policy makers in governments, institutions and 
health insurers, the use of F during orthodontic 
treatment is recommended for adoption as a policy. 
For most healthy patients undergoing orthodontic 
treatment, the use of F as a caries preventive measure 
is advocated. For patients who prefer to avoid F, 
appropriate advice from the clinician is recommended. 




In the present SR, the effect of interventions in the 
prevention of WSLs during orthodontic treatment 
was evaluated. Previous SRs have several limitations 
(Supplementary Table IV), including the inclusion 
of high-risk studies. These include in vitro, in vivo, 
ex vivo, retrospective, non-RCT and split mouth 
design studies (Supplementary Table V). It is critical 
to conduct sensitivity analyses to evaluate whether 
studies associated with a high risk of bias influence 
the pooled estimate. This aspect has been lacking in 
previous published SRs. Additionally, several SRs 
included studies that considered WSL inhibition 
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serious not serious  not serious  serious serious none  
⨁◯◯◯ 
VERY LOW2  
CPP-ACP 
2 randomised trials  serious not serious  not serious  serious serious none  
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serious not serious  serious serious not serious  none  
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serious not serious  serious  serious not serious  none  
⨁◯◯◯ 
VERY LOW5  
 
1 Moderate heterogeneity of 49.3% leads to serious inconsistency amongst the randomised trials. 
2 There were two sponsor funded studies, which could have biased their reporting. Low sample size leads to serious imprecision in the results.  
3 There was one sponsor funded trial, which could have biased their reporting. Low sample size leads to serious imprecision in the results. 
4 One study assessed the effect of caries risk and its impact on prophylactic procedures. This is an indirect measure for the outcome. Low sample size leads 
to serious imprecision in the results. 





Figure 4. Heterogeneity assessment.
Figure 5. GRADE evidence profile: caries prevention during orthodontic treatment.
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is unachievable with current interventions, it is 
imperative to prevent WSLs.40,41 This counters the 
undesirable aesthetic and biologic consequences of 
WSL development. 
The present review addressed these limitations 
through a rigorous approach. An a priori registration 
on the PROSPERO database, extensive search on 
multiple databases, and an independent analysis 
approach provided robustness in this review. The use 
of an updated Cochrane RoB 2 was also advantageous, 
since it identified an overall risk within the studies, 
and was less subjective compared to previous versions. 
Eight studies were excluded due to their short duration 
of less than six months. A longer time frame was a key 
eligibility criterion because a short follow-up period is 
likely to be insufficient for clinically detectable signs of 
dental caries to develop in many individuals. Even when 
carious lesions are detected early, prior to cavitation, 
the demineralisation process may have been present 
for months or years.2 The lack of adequate follow-up 
could lead to a type I error due to under-reporting 
of WSLs. Furthermore, several studies were excluded 
because they failed to include the presence of carious 
lesions (WSLs) as an outcome, and instead, resorted 
to report changes in microbiome, plaque and saliva. 
While these studies provided valuable insights into 
the mechanisms by which preventive measures reduce 
the risk of developing carious lesions, they cannot 
be considered equivalent to measuring the actual 
outcome of identifying WSLs. A reduction in certain 
cariogenic pathogens may not have an effect on WSL 
incidence, since the remineralisation-demineralisation 
balance is influenced by other factors.2 These surrogate 
measures cannot yet be utilised as accurate markers of 
clinical disease. 
The three RCTs included in the quantitative analysis 
investigated different F concentrations, and none 
were considered a low RoB. Two studies in the meta-
analysis did not have an initially calculated sample 
size.25,31 One RCT calculated the sample size required 
as 132 participants per group.25 Following attrition, 
this became 132 and 125 per group. Similarly, another 
RCT required 47 participants per group following 
their power calculation.31 Subsequent to dropouts, 
the groups were 36 and 45. These discrepancies could 
affect the statistical power of the studies, due to the 
risk of a type II error. One study had no pre-specified 
analysis plan, which created a potential for bias in the 
analysis post hoc.27 Although the outcome measures 
differed between the three RCTs as the analysis was 
based on the proportion of WSL incidence, this did 
not affect the synthesis. The heterogeneity obtained 
could be explained by the differing concentration and 
delivery vehicles of F in these trials. Since the number 
of studies assessed was low, heterogeneity analysis 
might be misleading due to decreased sensitivity.
The GRADE evaluation considers the number 
and design of studies in addition to effect sizes, 
which highlighted the lack of RCTs on the topic. 
The recommendation to use F during orthodontic 
treatment supports the current widespread usage 
by dental professionals.42 F therapy could include 
professional delivery as part of clinical care, or at-home 
use of F rinses and toothpastes. However, reported 
poor compliance with mouth rinsing by orthodontic 
patients reduces the clinical effectiveness of at-home 
therapies.43 Since F interventions alone provide a 
23% risk reduction of WSL development during 
orthodontic care, the combination of other preventive 
measures could reduce the risk further. Proper oral 
hygiene and non-cariogenic dietary practices in 
combination with F interventions may be of greater 
importance to reduce the risk of WSL incidence. 
The present review was unable to evaluate the cost-
effectiveness of interventions, as no appropriate 
studies were identified, an important consideration 
that is likely to favour at-home therapy. No RCTs 
were conducted to investigate the preventive effects 
of self-assembling peptides (SAP), RMGIC coatings 
and other calcium products such as TCPs.  The meta-
analysis was planned to be performed using Stata, but 
Jamovi statistical software was used, due to its open 
and free access.
Limitations
There are several limitations associated with this 
review. The World Health Organization International 
Clinical Trials Registry Platform was not sought for 
unpublished studies, which could have provided 
additional relevant papers. The exclusion of non-
English papers may have omitted well-conducted 
relevant studies. Since only three RCTs were pooled 
for meta-analysis, the estimates of risk difference may 
differ from the results obtained. Nevertheless, both 
random and fixed effects models provided similar 
outcomes. The results related to the inhibition of 
WSL progression and patient reported outcomes were 
not investigated in the included studies. 
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Study  
(year, country) Sample size Age of participants Intervention Control/ Comparison Frequency
Follow up 
period Outcome measure Baseline Outcome
Adverse 
effects





12-15 Fluoride varnish (Fluor Protector);  Antimicrobial varnish (Cervitec) Placebo and F varnish
Pre-bonding, Cervitec: 
weekly for 3 weeks. F 
varnish applied at bonding. 
Cervitec 6 weeks later | 
Both varnishes: 3 monthly 
afterwards
6 months WSL index
Experimental - mean 1.1 
SD 0.2; Control - mean 1.1 
SD 0.1
Experimental - mean 1.1 











Group 1: Tooth brush instruction, high 
potency and frequency F gel; Group 2: 
Tooth brush instruction, high potency and 
frequency dentrifice
Tooth brush instruction, 
low potency, high 
frequency F rinse
Control: 2/day brushing 
with 1.1% NaF dentrifice 
and 0.05% APF rinse; 
Group 1:  2/day brushing 
with 1.1% NaF dentrifice 
and 1.1% NaF gel; Group 
2: 2/day brushing with 
1.1% NaF dentrifice
Group 1 - 
27.1; Group 





Group 1 - 3.8 SD 5.8; 
Group 2 - 4.4 SD 6.8; 
Control - 2.1 SD 3.8
Group 1 - 6.4 SD 10.4; 
Group 2 - 6.0 SD 9.2 ; 
Control - 10.2 SD 14.2
None 
reported
Weiss et al.  
(2005, Germany)
68 (34 per 
group) Mean 14.1
Chlorhexidine gel in chair and 2.26% NaF 
varnish
40% chlorhexidine varnish 
and 2.26% NaF varnish
CHX 3 monthly. F varnish 4 
and 8 week rotations 10 months DMFS
Experimental - mean 10.9 
SD 2.5; Control - mean 
10.9 SD 4.5
Experimental - mean 15.1 
SD 4.5; Control - mean 
increase 14.4 SD 5.5
None 
reported





Mean 16.9 Modified F toothpaste technique: minimal rinsing of paste after brushing (1450 ppm F)
Regular brushing (1450 
ppm F) Daily practice 24 months DFS
Experimental - mean 8.3 
SD 7.5; Control - mean 8.1 
SD 8.4
Experimental - mean 9.0 




Hoffman et al.  
(2015, USA)
48 (24 per 
group)
Mean 15.6 in 
experimental group 
15.3 in control
5000ppm NaF with 5% NovaMin paste 1500ppm F toothpaste Daily practice 6 months Decalcification index
Experimental - mean 0.33 
SD 0.34; Control - mean 
0.33 SD 0.4
Experimental - mean 0.47 




Suetenkov et al.  
(2015, Russia)
60 (30 per 
group) 12-13.
Laser therapy (OPTODAN and FotoSan) with 
control goup regime
Twice daily brushing 
with 1400ppm F paste, 
0.05% CHX mouthrinse 
for 10 days, F gel
3 monthly 18 months DMFS
Experimental - mean 3.33 
SD 0.17; Control - mean 
3.76 SD 0.33
Experimental - mean 5.99 




Esenlik et al.  
(2016, Turkey)
40 (20 per 





[WSL Index] Experimental - 
mean 0; Control - mean 0
[WSL Index] Experimental - 
mean 1.9 SD 1.5; Control 
- mean 4.1 SD 4.0
None 
reported
Alavi et al.  
(2018, Iran)
40 (10 in each 
group) Mean 23
Group 1: 0.2% CHX varnish; Group 2: 5% 
NaF varnish
Group 3: placebo 
varnish; Group 4: control 3 monthly 9 months ICDAS
Group 1 - 1.5 SD 0.52; 
Group 2 - 1.4 SD 0.51; 
Group 3 - 1.1 SD 0.31; 
Group 4 - 1.1 SD 0.31
Group 1 - 1.1 SD 0.00; 
Group 2 - 1.0 SD 0.00; 
Group 3 - 1.2 SD 0.63; 
Group 4 - 1.30 SD 0.48
None 
reported
Gomeza et al.  
(2018, Spain)
20 (10 per 
group)
Mean 15.0 in 
experimental group 
14.2 in control
Photodynamic therapy - Methylene blue 
activated by laser at 670nm Ultrasonic scaler clean
2 weekly intially. Then three 
monthly 9 months ICDAS
Experimental - mean 0.14 
SD 0.03; Control - mean 
0.13 SD 0.02
Experimental - mean 0.21 









Median 15 40% chlorhexidine varnish Placebo 8 weekly median 21 months DMFS
Experimental - mean 10.5; 
Control - mean 8 
Experimental - mean 14.4; 
Control - mean 14.3
None 
reported





Mean 14.4 AmF/ SnF2 (1400ppm F) toothpaste and 250ppm F rinse
NaF (1400ppm F) 
toothpaste and 250ppm 
F rinse
2/day brush and 1/day 
rinse Debonding WSL index
Experimental - mean 1.02 
SD 0.08; Control - mean 
1.0 SD 0.02
Experimental - mean 1.05 









12-15. F varnish (0.1% F) Placebo varnish 6 weekly Debonding DMFS
Experimental - mean 2.8 
SD 4.2; Control - mean 2.7 
SD 3.8
Experimental - mean 7.62; 
Control - mean 19.34
None 
reported





10-20. 1.23% APF foam Placebo foam 2 monthly Debonding WSL index
Experimental - mean 0.31 
SD 1.07; Control - mean 
0.43 SD 1.68
Experimental - mean 1.02 






(2014, USA) 55 13 1.23% APF foam Placebo foam 2 monthly 6-8 months WSL index Experimental - 0; Control - 0









11-16. 5000ppm NaF paste 1450ppm NaF paste 2/day
Debonding 
(Mean 1.8 yrs 
SD 0.53)
WSL index
Experimental - mean 0.3 
SD 1.0; Control - mean 1.0 
SD 1.8
Experimental - mean 0.4 









Mean 13.3 250ppm F rinse (100ppm AmF, 150ppm NaF) Placebo rinse Daily practice
mean 24.5 
months DMFS and ICDAS Experimental - 0; Control - 0




Zotti et al.  
(2016, Italy)
80 (40 per 
group)
Mean 14.1 in study 
group 13.6 in control Whatsapp based reminder re OH No app based reminders Daily practice 12 months WSL index
[No of pts] Experimental - 4; 
Control - 5
[No of pts] Experimental - 
7; Control - 16
None 
reported






1100ppm F paste with MI Varnish (10% 
w/v CPP-ACP, 5% NaF) and MI Paste Plus 
(10% w/v CPP-ACP, 0.2% 900ppm NaF)
1100ppm F paste with 
0.05% NaF rinse
2/day F paste use; MI 
Varnish 3 monthly; MI Paste 






Experimental - mean 21.9 
SD 1.3; Control - mean 
21.1 SD 1.3 
Experimental - mean 22.3 
SD 1.4; Control - mean 
22.5 SD 1.5 
None 
reported
Supplementary Table III.  Data from studies included in the qualitative synthesis.
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Pre-bonding, Cervitec: 
weekly for 3 weeks. F 
varnish applied at bonding. 
Cervitec 6 weeks later | 
Both varnishes: 3 monthly 
afterwards
6 months WSL index
Experimental - mean 1.1 
SD 0.2; Control - mean 1.1 
SD 0.1
Experimental - mean 1.1 











Group 1: Tooth brush instruction, high 
potency and frequency F gel; Group 2: 
Tooth brush instruction, high potency and 
frequency dentrifice
Tooth brush instruction, 
low potency, high 
frequency F rinse
Control: 2/day brushing 
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and 0.05% APF rinse; 
Group 1:  2/day brushing 
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2: 2/day brushing with 
1.1% NaF dentrifice
Group 1 - 
27.1; Group 





Group 1 - 3.8 SD 5.8; 
Group 2 - 4.4 SD 6.8; 
Control - 2.1 SD 3.8
Group 1 - 6.4 SD 10.4; 
Group 2 - 6.0 SD 9.2 ; 
Control - 10.2 SD 14.2
None 
reported
Weiss et al.  
(2005, Germany)
68 (34 per 
group) Mean 14.1
Chlorhexidine gel in chair and 2.26% NaF 
varnish
40% chlorhexidine varnish 
and 2.26% NaF varnish
CHX 3 monthly. F varnish 4 
and 8 week rotations 10 months DMFS
Experimental - mean 10.9 
SD 2.5; Control - mean 
10.9 SD 4.5
Experimental - mean 15.1 
SD 4.5; Control - mean 
increase 14.4 SD 5.5
None 
reported





Mean 16.9 Modified F toothpaste technique: minimal rinsing of paste after brushing (1450 ppm F)
Regular brushing (1450 
ppm F) Daily practice 24 months DFS
Experimental - mean 8.3 
SD 7.5; Control - mean 8.1 
SD 8.4
Experimental - mean 9.0 




Hoffman et al.  
(2015, USA)
48 (24 per 
group)
Mean 15.6 in 
experimental group 
15.3 in control
5000ppm NaF with 5% NovaMin paste 1500ppm F toothpaste Daily practice 6 months Decalcification index
Experimental - mean 0.33 
SD 0.34; Control - mean 
0.33 SD 0.4
Experimental - mean 0.47 




Suetenkov et al.  
(2015, Russia)
60 (30 per 
group) 12-13.
Laser therapy (OPTODAN and FotoSan) with 
control goup regime
Twice daily brushing 
with 1400ppm F paste, 
0.05% CHX mouthrinse 
for 10 days, F gel
3 monthly 18 months DMFS
Experimental - mean 3.33 
SD 0.17; Control - mean 
3.76 SD 0.33
Experimental - mean 5.99 




Esenlik et al.  
(2016, Turkey)
40 (20 per 





[WSL Index] Experimental - 
mean 0; Control - mean 0
[WSL Index] Experimental - 
mean 1.9 SD 1.5; Control 
- mean 4.1 SD 4.0
None 
reported
Alavi et al.  
(2018, Iran)
40 (10 in each 
group) Mean 23
Group 1: 0.2% CHX varnish; Group 2: 5% 
NaF varnish
Group 3: placebo 
varnish; Group 4: control 3 monthly 9 months ICDAS
Group 1 - 1.5 SD 0.52; 
Group 2 - 1.4 SD 0.51; 
Group 3 - 1.1 SD 0.31; 
Group 4 - 1.1 SD 0.31
Group 1 - 1.1 SD 0.00; 
Group 2 - 1.0 SD 0.00; 
Group 3 - 1.2 SD 0.63; 
Group 4 - 1.30 SD 0.48
None 
reported
Gomeza et al.  
(2018, Spain)
20 (10 per 
group)
Mean 15.0 in 
experimental group 
14.2 in control
Photodynamic therapy - Methylene blue 
activated by laser at 670nm Ultrasonic scaler clean
2 weekly intially. Then three 
monthly 9 months ICDAS
Experimental - mean 0.14 
SD 0.03; Control - mean 
0.13 SD 0.02
Experimental - mean 0.21 









Median 15 40% chlorhexidine varnish Placebo 8 weekly median 21 months DMFS
Experimental - mean 10.5; 
Control - mean 8 
Experimental - mean 14.4; 
Control - mean 14.3
None 
reported





Mean 14.4 AmF/ SnF2 (1400ppm F) toothpaste and 250ppm F rinse
NaF (1400ppm F) 
toothpaste and 250ppm 
F rinse
2/day brush and 1/day 
rinse Debonding WSL index
Experimental - mean 1.02 
SD 0.08; Control - mean 
1.0 SD 0.02
Experimental - mean 1.05 









12-15. F varnish (0.1% F) Placebo varnish 6 weekly Debonding DMFS
Experimental - mean 2.8 
SD 4.2; Control - mean 2.7 
SD 3.8
Experimental - mean 7.62; 
Control - mean 19.34
None 
reported





10-20. 1.23% APF foam Placebo foam 2 monthly Debonding WSL index
Experimental - mean 0.31 
SD 1.07; Control - mean 
0.43 SD 1.68
Experimental - mean 1.02 






(2014, USA) 55 13 1.23% APF foam Placebo foam 2 monthly 6-8 months WSL index Experimental - 0; Control - 0









11-16. 5000ppm NaF paste 1450ppm NaF paste 2/day
Debonding 
(Mean 1.8 yrs 
SD 0.53)
WSL index
Experimental - mean 0.3 
SD 1.0; Control - mean 1.0 
SD 1.8
Experimental - mean 0.4 









Mean 13.3 250ppm F rinse (100ppm AmF, 150ppm NaF) Placebo rinse Daily practice
mean 24.5 
months DMFS and ICDAS Experimental - 0; Control - 0




Zotti et al.  
(2016, Italy)
80 (40 per 
group)
Mean 14.1 in study 
group 13.6 in control Whatsapp based reminder re OH No app based reminders Daily practice 12 months WSL index
[No of pts] Experimental - 4; 
Control - 5
[No of pts] Experimental - 
7; Control - 16
None 
reported






1100ppm F paste with MI Varnish (10% 
w/v CPP-ACP, 5% NaF) and MI Paste Plus 
(10% w/v CPP-ACP, 0.2% 900ppm NaF)
1100ppm F paste with 
0.05% NaF rinse
2/day F paste use; MI 
Varnish 3 monthly; MI Paste 






Experimental - mean 21.9 
SD 1.3; Control - mean 
21.1 SD 1.3 
Experimental - mean 22.3 
SD 1.4; Control - mean 
22.5 SD 1.5 
None 
reported
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Recommendations for future research
Future RCTs should explore the efficacy of 
interventions such as SAP, RMGIC, CPP-ACP and 
TCP on the prevention of WSLs during orthodontic 
treatment. Authors are encouraged to report on 
caries increment/lesion transition and adverse effects. 
Prospective RCTs should register their study protocols 
a priori and have a follow-up period of the duration 
of care, or otherwise at least six months. Future 
investigators are encouraged to design trials for patients 
undergoing removable orthodontic treatment.
Conclusions
• Based on the results of this SR, the use of 
supplementary fluoride is recommended for 
carious lesion prevention during fixed appliance 
orthodontic treatment. 
• Only low-quality evidence supports the use 
of CHX, CPP-ACP, OHI and lasers for caries 
prevention during orthodontic care.
• Fluoride-based preventive interventions provide 
a 23% risk reduction of WSL incidence during 
fixed appliance orthodontic treatment. 
• Additional well-conducted RCTs are required 
to provide caries preventive recommendations 
during fixed and removable appliance orthodontic 
treatment. 
• The investigation of newer interventions is 
required to update this clinical guideline.
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Figure 6. Pooled risk difference obtained from a fixed-effects model. 
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Authors Title Reason Exclusion stage
Adiaens et al. (1990) The use of ‘Fluor Protector®’, a fluoride varnish, as a caries prevention method under orthodontic molar bands. In vitro Title/abstract screen
Twetman et al. (1995) Effect of an antibacterial varnish on mutans streptococci in plaque from enamel adjacent to orthodontic appliances Surrogate outcome Title/abstract screen
Madléna et al. (2000) Effect of chlorhexidine varnish on bacterial levels in plaque and saliva during orthodontic treatment Surrogate outcome Title/abstract screen
Demito et al (2004) 
The efficacy of a fluoride varnish in reducing enamel 
demineralization adjacent to orthodontic brackets: an in vitro 
study.
In vivo Title/abstract screen
Skold-Larsson, K. et al. (2004)
Effect of topical applications of a chlorhexidine/thymol-
containing varnish on fissure caries assessed by laser 
fluorescence
Non RCT Title/abstract screen
Luther et al. (2005) Fluoride releasing glass beads in orthodontic treatment to reduce decay: a randomized, controlled clinical trial.
Outcome not 
reported Title/abstract screen
Vivaldi-Rodrigues et al. (2006) The effectiveness of a fluoride varnish in preventing the development of white spot lesions
Split mouth + <6 
months Title/abstract screen
Farhadian N, et al (2008) Effect of fluoride varnish on enamel demineralization around brackets: an in-vivo study In vivo Title/abstract screen
Bailey et al. (2009) Regression of post-orthodontic lesions by a remineralizing cream Post-orthodontic Title/abstract screen
Beerens et al. (2010)
Effects of casein phosphopeptide amorphous calcium fluoride 
phosphate paste on white spot lesions and dental plaque after 
orthodontic treatment: a 3-month follow-up
< 6 months Title/abstract screen
Baeshen et al. (2011) Effect of fluoridated chewing sticks (Miswaks) on white spot lesions in postorthodontic patients Post-orthodontic Title/abstract screen
Brochner et al. (2011) Treatment of post-orthodontic white spot lesions with casein phosphopeptide-stabilised amorphous calcium phosphate Post-orthodontic Title/abstract screen
Enaia et al. (2011) White-spot lesions during multibracket appliance treatment: A challenge for clinical excellence. Non RCT Title/abstract screen
Richter et al. (2011) Incidence of caries lesions among patients treated with comprehensive orthodontics Retrospective Title/abstract screen
Robertson et al. (2011) MI Paste Plus to prevent demineralization in orthodontic patients: a prospective randomized controlled trial < 6 months Title/abstract screen
Shinaishin et al. (2011) Efficacy of light-activated sealant on enamel demineralization in orthodontic patients: an atomic force microscope evaluation Ex vivo Title/abstract screen
Akin et al. (2012) Can white spot lesions be treated effectively? Post-orthodontic Title/abstract screen
Du et al. (2012) Randomized controlled trial on fluoride varnish application for treatment of white spot lesion after fixed orthodontic treatment Post-orthodontic Title/abstract screen
Jumanca et al. (2012)
Infiltration Therapy-an Alternative to Fluoride Varnish 
Application for Treatment of White Spot Lesion After Fixed 
Orthodontic Treatment.
Post-orthodontic Title/abstract screen
Huang et al. (2013)
Effectiveness of MI Paste Plus and PreviDent fluoride varnish 
for treatment of white spot lesions: a randomized controlled 
trial
Post-orthodontic Title/abstract screen
Baroni et al. (2014)
A SEM and non-contact surface white light profilometry in 
vivo study of the effect of a creme containing CPP-ACP and 
fluoride on young etched enamel
In vivo Title/abstract screen
Restrepo et al. (2015) Control of white spot lesion adjacent to orthodontic bracket with use of fluoride varnish or chlorhexidine gel In vivo Title/abstract screen
He et al. (2016)
Comparative assessment of fluoride varnish and fluoride film 
for remineralization of postorthodontic white spot lesions in 
adolescents and adults over a 6-month period: a single-center, 
randomized controlled clinical trial,
Post-orthodontic Title/abstract screen
Supplementary Table V.  Reasons for exclusion of studies included by previous SRs.
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Restrepo et al. (2016)
Control of White Spot Lesions with Use of Fluoride Varnish 
or Chlorhexidine Gel During Orthodontic Treatment A 
Randomized Clinical Trial.
< 6 months Title/abstract screen
Kirschneck et al. (2016)
Efficacy of fluoride varnish for preventing white spot lesions 
and gingivitis during orthodontic treatment with fixed 
appliances-a prospective randomized controlled trial
< 6 months Title/abstract screen
Singh et al. (2016) Effects of various remineralizing agents on the outcome of post-orthodontic white spot lesions (WSLs): a clinical trial Post-orthodontic Title/abstract screen
Turska-Szybka et al. (2016)
Randomised Clinical Trial on Resin Infiltration and Fluoride 
Varnish vs Fluoride Varnish Treatment Only of Smooth-surface 
Early Caries Lesions in Deciduous Teeth.
Non-orthodontic Title/abstract screen
Bock et al. (2017)
Changes in white spot lesions following post-orthodontic 
weekly application of 1.25 per cent fluoride gel over 6 
months-a randomized placebo-controlled clinical trial. Part I: 
photographic data evaluation
Post-orthodontic Title/abstract screen
Bock et al. (2017)
Changes in white spot lesions following post-orthodontic 
weekly application of 1.25 per cent fluoride gel over 6 
months-a randomized placebo-controlled clinical trial. Part II: 
clinical data evaluation
Post-orthodontic Title/abstract screen
Ebrahimi et al. (2017)
The effects of three remineralizing agents on regression of 
white spot lesions in children: a two week, single-blind, 
randomized clinical trial
< 6 months Title/abstract screen
Karabekiroglu et al. (2017) Treatment of post-orthodontic white spot lesions with CPP-ACP paste: A three year follow up study Post-orthodontic Title/abstract screen
Beerens et al. (2018)
Long-term remineralizing effect of MI Paste Plus on regression 
of early caries after orthodontic fixed appliance treatment: a 
12-month follow-up randomized controlled trial
Post-orthodontic Title/abstract screen
Heravi et al. (2018)
Effectiveness of MI Paste Plus and Remin Pro on 
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